BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1 Merus and Partner Therapeutics announced a license agreement for U.S. commercialization  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec.  04, 2024  (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) [Merus, the Company, we, or our], a clinical-stage oncology comp…

Benzinga

New York

United States

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study - Merus (NASDAQ:MRUS)

Ad Fontes Media

Media Bias/Fact Check

The US Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus) as an intravenous infusion for

Medscape

FDA approves Bizengri for NSCLC, pancreatic cancer

Merus (MRUS) has received accelerated FDA approval for its drug Bizengri for the treatment of NRG1+ cancers of the pancreas and lung. Read more here.

Seeking Alpha

Merus gets FDA approval for Bizengri for NRG1+ cancers (NASDAQ:MRUS)

Source link : https://www.newshealth.biz/health-news/fda-oks-first-drug-targeting-nrg1-gene-fusion-in-pancreatic-lung-cancers/ The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday. The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy. Zeno…

Your Blog Domain

FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers – Your Blog Domain

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1 Merus and Partner Therapeutics announced a license agreement for U.S. commercialization  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology compan…

Business Upturn

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell

MedPage Today

FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers

Merus, N.V.  announced  that the US FDA approved BIZENGRI®, a  treatment indicated for adults with pancreatic adenocarcinoma or NSCLC that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. [Merus, N.V.]  Press Release

Stemwell Science News

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1 Merus and Partner Therapeutics announced a license agreement for U.S. commercialization  UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I December 04, 2024 I Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developi…

pipelinereview

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study - Pipelinereview

Dec 5, 2024 - By Erin PostThe U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic adenocarcinoma, the most common type of pancreatic cancer. This approval underscores the promise of precision medicine – treatment based on the biology of a patient’s tumor – and reinforces how critical it is for all patients with this …

Pancreatic Cancer Action Network

FDA Approves New Targeted Therapy for NRG1 Fusion-Positive Pancreatic Cancer: What You Need to Know

In a significant milestone for cancer treatment, Merus N.V. has received the U.S. Food and Drug Administration (FDA) approval for BIZENGRI (zenocutuzumab-zbco), marking a breakthrough in the fight against advanced pancreatic adenocarcinoma and nonsmall cell lung cancer (NSCLC) associated with a neuregulin 1 (NRG1) gene fusion. This pioneering therapy is now the first and only treatment approved specifically for adults battling these aggressive c…

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study - Merus (NASDAQ:MRUS)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics